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Denaturing High-Performance Liquid Chromatography for Detecting
and Typing Genital Human Papillomavirus
Jianduan Li,1 Daniela S. Gerhard,2† Zhengyan Zhang,1 Phyllis C. Huettner,3
Jason Wright,1 Loan Nguyen,1 Danielle Lu,3 and Janet S. Rader1,2*
Departments of Obstetrics and Gynecology,1 Genetics,2 and Pathology,3 Washington
University School of Medicine, St. Louis, Missouri 63110
Received 18 June 2003/Returned for modification 16 July 2003/Accepted 20 August 2003
Human papillomaviruses (HPVs) are important in the development of human cancers, including cervical
and oral tumors. However, most existing methods for HPV typing cannot routinely distinguish among the more
than 100 distinct types of HPV or the natural HPV intratypic variants that have also been documented. To
address this problem, we developed a novel method, general primer-denaturing high-performance liquid
chromatography (GP-dHPLC), for the detection and typing of genital HPV using an automated 96-well plate
format. GP-dHPLC uses general primer PCR (GP-PCR) to amplify the viral DNA and then analyzes the
GP-PCR products by denaturing high-performance liquid chromatography (dHPLC). A number of different
primer pairs with homology to most known genital HPV types were tested, and the L1C1-L1C2M pair specific
for the L1 region of the viral genome was chosen. A set of HPV standard control patterns, consisting of those
for HPV types 16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59, 6, and 11, was established for genital HPV typing. One
hundred eighty-six frozen and formalin-fixed cervical cancer tissue samples were analyzed for the presence of
HPV and the HPV type by this method, and 95.8% of them were found to contain HPV DNA. GP-dHPLC
accurately discriminated among HPV variants that differed by as little as one nucleotide. Several new variants
of HPV types 16, 18, 39, 45, 52, and 59 were identified. Moreover, multiple HPV infections were detected in
26.6% of the samples. Our results indicate that HPV typing by GP-dHPLC permits discrimination of common
genital HPV types, detection of multiple HPV infections, and identification of HPV variants in clinical samples.
Human papillomaviruses (HPVs) form a heterogeneous
group whose genome is an 8-kb double-stranded circle of
DNA. They are the most diverse group of DNA viruses in-
volved in human disease. More than 100 putative HPV types
have been described to date, including 85 that have been
cloned and officially designated and others that have been
identified from the sequences of PCR products. More than 40
types of HPV are sexually transmitted; these are called genital
HPVs. The genital HPVs can be grouped on the basis of their
clinical associations and in vitro transforming capabilities into
high-risk types (e.g., HPV types 16 and 18), intermediate-risk
types (e.g., HPV types 31 and 33), and low-risk types (e.g.,
HPV types 6 and 11) (8, 16, 20). HPV is considered the major
etiological agent of cervical cancer and its precursor lesions
throughout the world (3). The majority of invasive cervical
cancers and high-grade lesions are associated with high-risk
and intermediate-risk HPV infections, while most low-grade
dysplastic lesions and benign condylomata acuminata are as-
sociated with low-risk HPV types (3, 8, 16, 20, 22, 34).
Nucleic acid sequencing has revealed the existence of many
natural sequence variations among HPV types. HPV genomes
that vary from that of the prototype by 2% are defined as
“variants,” whereas those that diverge by 10% from the ge-
nome of any described HPV type qualify as independent types.
Isolates whose genomes differ from that of an established type
by 2 to 10% are considered subtypes (30). A number of HPV
variants for high-risk, intermediate-risk, and low-risk types
have been described to date (11). More than 40 naturally
occurring variants have been classified (10, 11, 13); their bio-
logical and biochemical properties differ in vitro (26), and their
oncogenicities also differ (13, 19, 36). Several studies have
indicated that viral persistence and the development of high-
grade lesions and invasive carcinomas are closely associated
with the presence of specific HPV variants (1, 2, 4–7, 10, 15, 18,
21, 31, 40).
Given the different oncogenic potentials of the various HPV
types and variants, HPV genotyping is becoming increasingly
important as a diagnostic aid and prognostic tool. Recently,
HPV detection has been proposed as an alternative to cyto-
logical screening for cervical cancer (24, 32, 33).
Two main approaches are used for HPV detection and typ-
ing: (i) general primer PCR (GP-PCR) (also referred to as
degenerate or consensus primer PCR), which amplifies a con-
served region in the virus followed by HPV type-specific iden-
tification, and (ii) the hybrid capture assay, which detects and
types HPV by direct hybridization with type-specific RNA
probes (25). A variety of general primers are available for the
detection of HPV through GP-PCR (9, 23, 28, 37, 38). These
primer sets are designed to match the short regions of homol-
ogy among the HPV genotypes. For example, GP5-GP6
(28), MY11-MY09 (23), and L1C1-L1C2 (37) from the L1
region and pU-1M–pU-2R (38) from the E6/E7 region can
detect a broad spectrum of known and unknown HPV DNAs.
* Corresponding author. Mailing address: Department of Obstetrics
and Gynecology, Division of Gynecologic Oncology, Washington Uni-
versity School of Medicine, Box 8064, 4911 Barnes-Jewish Hospital
Plaza, St. Louis, MO 63110. Phone: (314) 362-3181. Fax: (314) 362-
2893. E-mail: raderj@msnotes.wustl.edu.
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Because of similarities between the GP-PCR products, how-
ever, it remains difficult to accurately differentiate among the
genital HPV types. A variety of techniques, including DNA
hybridization with type-specific probes (12, 28), type-specific
PCR (27), multiplex PCR with type-specific antisense primers
(14), single-strand conformation polymorphism analysis (39),
restriction fragment length polymorphism analysis (9, 37), en-
zyme-linked immunosorbent assay (17), and direct sequence
analysis (29), have been used in combination with GP-PCR to
facilitate HPV typing. Each detection method has advantages
and disadvantages, but most are unable to discriminate among
multiple HPV types and variants.
Denaturing high-performance liquid chromatography
(dHPLC) separates PCR products by size and sequence. It
detects the sequence divergence of DNA fragments, including
single base substitutions and short deletions and insertions.
This technology is sufficiently sensitive for the reliable detec-
tion of nearly 100% of DNA sequence variations at optimized
partially denaturing temperatures (35). We therefore devel-
oped a novel method for the detection and typing of genital
HPV that uses a combination of GP-PCR and dHPLC (re-
ferred as general primer-dHPLC [GP-dHPLC]). The method
allows us to discriminate among common genital HPV types,
to detect multiple HPV infections, and to identify HPV vari-
ants from clinical samples. Moreover, samples can be pro-
cessed in a 96-well format and continuously loaded on the
column for analysis.
MATERIALS AND METHODS
HPV controls. We used HPV controls to evaluate the sensitivities of the
GP-PCR primers and to establish the gradient conditions for dHPLC to establish
the optimal conditions and standard pattern for HPV typing. Subclones of HPV
genomes were kindly provided by Lou Laimins at Northwestern University (HPV
types 6, 11, 16, 18, 31, 33, 35, and 42), E.-M. de Villiers at Deutsches Krebsfors-
chungszentrum in Heidelberg, Germany (HPV types 45 and 51), and Wayne D.
Lancaster at Wayne State University School of Medicine (HPV type 52). Con-
trols for HPV types 39, 56, 58, and 59 were identified from cervical cancer tissue
samples. All HPV controls were confirmed by bidirectional sequencing of their
PCR products.
Cervical cancer tissue samples. Cervical cancer tissue samples were obtained
from pathological specimens from patients with invasive cervical carcinomas.
Thirty-six samples were snap-frozen in liquid nitrogen, 169 were embedded in
Optimal Cutting Temperature compound (Sakura Finetek Inc., Torrance, Calif.)
and frozen in isobutane, and 41 were in formalin-fixed, paraffin-embedded tissue
blocks. All cervical tissue specimens were reviewed by a gynecologic pathologist
(P.C.H. or D.L.) to confirm the diagnosis of invasive cervical cancer. Four to
eight 10-m sections from each tumor were placed in a sterile microcentrifuge
tube. The microtome blade was changed for the preparation of each tumor.
HPV-negative control tissue from normal human spleen and ovary tissues were
used to verify that no cross-contamination occurred between samples. DNA was
extracted by the standard sodium dodecyl sulfate-proteinase K procedure, puri-
fied with phenol-chloroform, resuspended in TE (Tris-EDTA) buffer (pH 8.0),
and then quantitated. The study was approved by the Washington University
Human Studies Committee.
PCRs. Several general primer sets were tested (Table 1). The PCR mixture
contained 50 mM KCl, 10 mM Tris-Cl (pH 8.4), 1.0 mM MgCl2, 100 M each
deoxynucleoside triphosphate, 1 M each primer, and a mixture (9:1; vol/vol) of
5 U of AmpliTaq (Applied Biosystems, Foster City, Calif.) per l with 2.5 U of
Pfu (Stratagene, La Jolla, Calif.) per l and 40 ng of genomic DNA (or 40 pg of
plasmid HPV DNA) in a final volume of 20 l. The general PCR program was
94°C for 2 min, 94°C for 30 s, 40 to 47°C (1°C increase each cycle) for 30 s, and
72°C for 1 min for 8 cycles and then 94°C for 30 s, 48°C for 30 s, and 72°C for 1
min for 35 cycles on a PCR Express thermal cycler (Hybaid, Franklin, Mass.).
The presence of PCR products was confirmed by 2% agarose gel electrophoresis
and ethidium bromide staining.
HPV typing by dHPLC. Genotyping of the amplified GP-PCR products was
performed by dHPLC with the WAVE Nucleic Acid Fragment Analysis System
(Wave system; Transgenomic, Inc., San Jose, Calif.). The reagents used were
buffer A (0.1 M triethylammonium acetate [TEAA], 0.025% [vol/vol] acetoni-
trile) and buffer B (0.1 M TEAA, 25% [vol/vol] acetonitrile); all reagents were
purchased from Transgenomic, Inc.
dHPLC uses the principles of reverse-phase ion-paired chromatography to
separate PCR products. The chromatographic column (DNASep column) in the
Wave system is packed with C18 alkylated polystyrene-divinylbenzene polymeric
beads. A positively charged ion-pairing reagent (TEAA) allows the negatively
charged DNA to interact with the hydrophobic DNASep column matrix. An
increasing proportion of organic mobile phase (acetonitrile) is used to elute the
DNA fragments from the matrix in a size-dependent manner (for nondenaturing
conditions) and a sequence-dependent manner (for partially and fully denaturing
conditions), and the fragments are detected by UV analysis. For our analysis, we
set the temperature high enough to partially denature DNA duplexes. GP-PCR
products with sequence divergence have different retention times on the column.
Identical HPV types elute as a single peak, whereas different HPV types or
TABLE 1. General primer sets
Primer name ORF
a of
viral genome Primer sequence (5-3) Primer location
b PCR product
size (bp) Reference(s)
L1C1 L1 CGTAAACGTTTTCCCTATTTTTTT 5609–5632 243–262 9, 37
L1C2 TACCCTAAATACTCTGTATTG 5841–5861
(L1C2M) (TACCCTAAATACCCTATATTG) (5841–5861)
GP5 L1 TTTGTTACTGTGGTAGATAC 6624–6643 139–149 25
GP6 GAAAAATAAACTGTAAATCA 6746–6765
L1S-L L1 TTTAATAAACCATATTGGTTACA 6555–6577 89 —c
L1S-R GTATCCACAACAGTAACAAA 6624–6643




E6-L E6 ACCGAAAACGGTTCATATAAA 50–70 192–212 —c
E6-R AAATGCAAATTCATATACCTC 224–244
a ORF, open reading frame.
b Primer location refers to the sequence of HPV type 16 (GenBank accession no. K02718).
c —, new primer design.
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variants elute in double peaks or in a single peak containing a shoulder or having
a retention time different from that of the control sample.
We optimized the temperature, gradient conditions, and flow rates on the
Wave system to differentiate among the most common high- and intermediate-
risk genital HPV types. HPV genotypes were determined by mixing each sample
with an HPV control and comparing the results with those for standard HPV
controls. PCR products whose peaks differed from those of the HPV controls
were sequenced. Multiple peaks were isolated for sequencing by using the Frag-
ment Collector of the Wave system. The samples were also automatically quan-
titated by the Wave system according to peak area.
Sequencing. A 5-l aliquot from the PCR mixture was treated by use of the
ExoSAP-IT kit (U.S. Biochemical Corporation, Cleveland, Ohio), according to
the instructions of the manufacturer, and was then used as the sequencing
template without further purification. Direct sequencing was performed with the
BigDye Terminator sequencing kit (version 3.0; Applied Biosystems). Sequenc-
ing reaction products were run on an ABI Prism 3100 Genetic Analyzer (Applied
Biosystems). The DNA sequences were compared by using DNAStar software
(DNAStar, Inc., Madison, Wis.).
RESULTS
Selection of general primer set for GP-PCR. Several general
primer sets are available for the detection of HPV in clinical
specimens. They are designed to match the short regions of
conserved homology among the HPV genotypes. The primer
sets evaluated in this study are presented in Table 1. We also
designed and tested two additional sets: L1S-L and L1S-R
from the L1 region and E6-L and E6-R from the E6 region
(Table 1). We compared mismatches between the general
primer sets and genital HPV DNA templates. The results of
the comparisons are displayed in Table 2.
The L1C1-L1C2M, L1S-L–L1S-R, pU-1M–pU-2R, and
E6-L–E6-R primer sets were further tested for their abilities to
amplify HPV by using plasmids with HPV type 16, 18, 31, 33,
6, and 11 DNA. All the primer sets worked well with all of
these major HPV types. The smallest amount of each virus that
was detectable depended on the number of mismatches be-
tween the primer and the template. HPV types with fewer
mismatches were easier to amplify. Primer sets containing a
mismatch of 5 nucleotides did not consistently amplify HPV
DNA (data not shown). We chose the L1C1-L1C2M primer set
for use with clinical samples because its sequence had few
mismatches when it was used with high- and intermediate-risk
HPV types (Table 2). Also, the size of the product permitted
good amplification from samples embedded in paraffin and
separation by dHPLC.
Establishment of a set of HPV standard control patterns.
The resolution of DNA fragments by dHPLC depends on
several factors, including the denaturing temperature, the gra-
dient concentrations of buffer A and buffer B, flow rate, slope,
and run time. All these factor need to be optimized to distin-
guish among the GP-PCR products of the common genital
HPV types.
To determine the temperature at which the different HPV
PCR products could be distinguished, we performed a temper-
ature titration of the GP-PCR products from the most com-
monly encountered HPV types, types 16, 18, 31, and 33, using
a temperature range of 50 to 64°C. Samples containing indi-






No. of nucleotide mismatches
GP5/GP6 L1C1/L1C2 L1C1/L1C2M pU-1M/pU-2R pU-1M-L/pU-2R-N L1S-L/L1S-R E6-L/E6-R
16 (HR) K02718 2/0 2/3 2/3 3/2 4/7 2/1 3/2
18 (HR) X05015 0/1 1/2 1/2 4/5 5/0 0/2 2/1
31 (IR) J04353 0/2 4/3 4/1 1/2 1/7 2/2 3/3
33 (IR) A12360 0/2 1/4 1/2 2/1 4/6 2/2 2/1
35 (IR) M74117 2/0 5/0 5/3 1/3 3/8 1/2 3/3
39 (IR) M62849 4/2 1/5 1/3 3/8 4/3 3/2 3/0
45 (IR) X74479 3/0 1/5 1/3 6/6 7/1 1/2 2/2
51 (IR) M62877 6/3 2/1 2/1 6/10 7/5 4/5 1/5
52 (IR) X74481 4/1 1/4 1/4 4/2 5/7 2/2 3/5
53 (IR) X74482 3/4 2/5 1/3 4/9 6/4 3/1 1/3
56 (IR) X74483 1/3 1/2 1/0 5/10 7/5 2/2 1/4
58 (IR) D90400 2/2 1/5 1/3 2/2 3/7 3/3 3/2
59 (IR) X77858 4/2 1/1 1/3 5/7 8/4 2/4 1/2
66 (IR) U31794 2/4 1/3 1/3 7/10 9/5 2/0 0/5
68 (IR) M73258 3/3 3/4 3/4 5/8 8/3 5/1 2/1
70 (IR) U21941 3/2 1/3 1/1 4/9 5/4 3/3 2/0
82 (IR) AF293961 6/2 2/4 2/2 4/10 8/5 2/5 1/5
6b (LR) X00203 0/1 3/3 3/3 4/3 5/8 2/2 6/6
11 (LR) M14119 0/0 3/3 3/3 4/3 6/8 2/2 6/5
26 (LR) X74472 5/3 3/4 3/4 5/11 5/6 2/6 2/4
34 (LR) X74476 3/5 3/3 3/3 3/10 3/5 3/3 4/3
40 (LR) X74478 3/1 9/1 9/1 5/9 8/4 5/3 2/9
42 (LR) M73236 3/4 4/3 4/5 5/11 9/6 0/4 3/10
43 (LR) U12504 —/—c —/— —/— 7/— 9/— —/3 3/8
44 (LR) U31788 1/3 4/6 4/4 5/9 6/4 4/1 5/3
54 (LR) NC_001676 4/1 3/4 2/2 6/8 9/4 2/4 2/6
73 (LR) X94165 3/1 5/4 5/4 3/11 6/6 2/3 2/1
a The published primer sequence was compared to HPV DNA sequences obtained from GenBank (http://www.ncbi.nlm.nih.gov) and the HPV sequence database
at Los Alamos National Laboratory (http://hpv-web.lanl.gov).
b HR, high risk; IR, intermediate risk; LR, low risk.
c —, for HPV type 43, only a partial sequence is available from the indicated sources.
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vidual HPV types as well as mixtures of different types were
tested. Samples containing just one HPV type gave a single
peak over the entire temperature range (Fig. 1A), whereas
samples containing two HPV types displayed two clearly sep-
arated peaks only between 56 and 58°C (Fig. 1B). We therefore
selected the temperature range 56 to 58°C for further testing.
The temperature titration revealed that each HPV type had
a specific retention time at a given temperature (data not
shown). Therefore, we mixed the most common genital HPV
types together in order to establish an HPV standard control
pattern for future HPV typing. After optimizing the denatur-
ing temperature, gradient concentration, flow rate, slope, and
run time, we established a set of standard control patterns for
HPV typing on the Wave system. The set included the general
standard pattern and standard patterns for groups I to IV. The
conditions used to obtain these standard control patterns are
listed in Tables 3 and 4.
The general standard pattern included six of the most com-
mon high-risk and intermediate-risk HPV types (HPV types
16, 31, 33, 51, 52, and 18). The HPV types are displayed from
left to right in the chromatograph in Fig. 2. This general stan-
dard pattern was used as the preliminary typing step. It was not
precise enough to distinguish among all the common genital
HPV types.
The final identification of HPV types was achieved by mixing
each sample with an HPV control, running the mixture under
one of the four subgroup conditions, and then sequencing the
products with novel peaks, i.e., variants and novel types (Fig.
3). Each subgroup contains one to four HPV types, and the 13
HPV types in Fig. 3 comprise over 95% of the viruses to be
identified. The subgroups were determined by comparing the
FIG. 1. Temperature titration of individual GP-PCR products and mixtures of GP-PCR products. GP-PCR products were amplified by using
primers L1C1-L1C2M. HPV controls were run through a temperature gradient of 50 to 64°C. (A) Temperature titration of HPV type 16 GP-PCR
product. The eluted peak for HPV is between 3 and 6 min; the large peak at 7 min is what was washed off between two samples. (B) Temperature
titration of a mixture of GP-PCR products from both HPV type 16 and HPV type 18. The two separate well between 53 and 59°C.








General 13.2 0.9 1.2 57
I 10.1 0.6 1.2 57
II 10.8 0.5 1.2 58
III 10.1 0.6 1.2 58.9
IV 17.6 0.4 0.12 57.4
a See Fig. 3 for the HPV composition of each group.
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retention times of the most common viral types through the
column.
The precise compositions of buffers A and B are key factors
affecting the retention times and resolutions of the peaks.
Thus, HPV peaks shifted slightly between batches of buffer,
creating the possibility of assigning a sample to the wrong
control. To catch such errors, we ran HPV standard controls
after about every 10 to 15 samples were run.
Use of GP-dHLPC to detect and type clinical specimens.
Detection and typing of HPV in clinical specimens were per-
formed in three steps. First, HPV was detected by GP-PCR
with the L1C1-L1C2M general primer set. The presence and
size of the PCR products were ascertained by agarose gel
electrophoresis. Second, each GP-PCR product was analyzed
with the Wave system. The general standard pattern condition
was used to compare the retention time of the DNA sample to
that of the control HPV and to assign each sample to one of
four groups (Fig. 4A). Finally, each GP-PCR product (or a
single DNA peak collected from the column) was mixed with
an equal amount of the control that displayed a similar reten-
tion time or with the most prevalent HPV type encountered
within its group. The mixtures were analyzed on the Wave
system by using a group-specific standard pattern condition
(Fig. 4B and C). Thus, samples assigned to group I were mixed
with HPV type 16, samples assigned to group II were mixed
with HPV type 31 or 33 (depending on the sample’s position
during the first run), samples assigned to group III were mixed
with HPV type 51, and samples assigned to group IV were
mixed with HPV type 18, 52, or 45. If the mixture produced a
single peak with the same retention time as that for the known
HPV control, the HPV genotype of the sample was confirmed.
If the mixture revealed a shoulder or double peak (Fig. 4C,
samples 271, 391, and 419), it was assumed that a different
HPV type or variant was present. In this case, the DNA prod-
uct was sequenced from both ends to determine the genotype.
We analyzed 186 cervical tissue samples for the presence
and type of HPV. More than 95% of the samples were infected
with the virus. The validity of HPV genotyping was obtained by
direct sequencing of 12 PCR products from several HPV types.
In addition, all samples that displayed a peak different from
that displayed by the HPV control were sequenced, and in all
cases a different type or variant was identified. We discovered
25 HPV variants in all: 12 HPV type 16 variants; 8 HPV type
18 variants; 2 HPV type 59 variants; and 1 variant each of HPV
types 45, 52, and 39 (Table 5). Every variant was confirmed by
bidirectional sequencing. The sequences of the HPV variants
differed from the HPV prototype recognized in GenBank by 1
to 5 bp. Because of the degeneracy of the genetic code, not all
of the HPV variants had altered amino acid sequences.
Multiple HPV infections were detected in 26.6% of the
FIG. 2. HPV general standard pattern. The general standard pattern is that obtained with a mixture of six common high-risk and intermediate-
risk HPV types: types 16, 31, 33, 51, 52, and 18. The PCR products for these controls are mixed together and are shown on the top elution run.
The retention time is unaffected by mixing, as can be seen by the run for each individual sample below. The gradient conditions for this general
standard pattern are presented in Tables 3 and 4.
TABLE 4. Five different gradient conditions for HPV genotypinga
Step
General Group I Group II Group III Group IV
Time
(min) % A % B
Time
(min) % A % B
Time
(min) % A % B
Time
(min) % A % B
Time
(min) % A % B
Loading 0.0 49 51 0.0 49 51 0.0 49 51 0.0 48 52 0.0 47 53
Start gradient 0.5 48 52 0.5 48 52 0.5 48 52 0.5 47 53 0.5 46 54
Stop gradient 7.3 45 55 5.0 47 53 5.0 47 53 5.0 46 54 9.0 45 55
Start clean 7.4 0 100 5.1 0 100 5.1 0 100 5.1 0 100 9.1 0 100
Stop clean 7.9 0 100 5.6 0 100 5.6 0 100 5.6 0 100 9.5 0 100
Start equilibrate 8.0 49 51 5.7 49 51 5.7 49 51 5.7 48 52 9.6 47 55
Stop equilibrate 11.0 49 51 6.8 49 51 6.8 49 51 6.8 48 52 12.6 47 55
a See Fig. 3 for the HPV composition of each group. A and B refer to buffers A and B, respectively, as defined in the text.
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cervical cancer tissue samples. GP-dHLPC could identify mul-
tiple HPV infections easily and reliably by detecting multiple
peaks (Fig. 4A, sample 408). The HPV types in the majority of
samples infected with multiple HPV types could be determined
by mixing the PCR product with multiple HPV controls, par-
ticularly if two different groups were used in the second run
(Fig. 4A and B). When a new peak was noted for a sample
containing more than one HPV variant or type, we used the
Wave system’s Fragment Collector to isolate the peaks before
sequencing the fragments.
FIG. 3. Standard patterns for groups I to IV. After the unknown sample is mixed with the control with which it is most likely to match, the mixed
sample is run under one of four conditions: panel 1, the group I standard pattern is for HPV type 16 only; panel 2, the group II standard pattern
includes HPV types 31, 33, 11, and 58; panel 3, the group III standard pattern includes HPV types 59, 56, 51, and 6; panel 4, the group IV standard
pattern includes HPV types 18, 52, 39, and 45. The gradient condition for each standard pattern is presented in Tables 3 and 4.
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We have developed a novel method for genotyping genital
HPV that uses GP-PCR followed by dHPLC on the Wave
system. The Wave system is a commercially available auto-
mated technology for detecting variations in DNA sequences.
The PCR products can be processed in a 96-well format and
continuously loaded on the column for analysis without any
initial purification. This technique allows reliable discrimina-
FIG. 4. HPV genotyping of cervical cancer tissue specimens. (A) A first run of the HPV general standard pattern followed by the PCR product
of four unknown samples. (B) The second run mixes the unknown samples with HPVs from group IV. Because each sample in the mixture produces
a sharp peak, it is easy to deduce that the sequence of sample 408 is identical to that of HPV type 18, that the sequence of sample 162 matches
that of HPV type 52, and that the sequence of sample 246 matches that of HPV type 45. (C) A second run that mixes unknown samples with HPV
type 16 by using group I conditions. The peaks produced by samples 271, 391, and 419 contain a shoulder; sequencing of the PCR product revealed
an HPV type 16 variant.
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tion of the most common genital HPV types detected by the
consensus PCR primers as well as identification of HPV vari-
ants whose sequences diverge by as little as 1 nucleotide in a
250-bp segment of the HPV L1 region. It can also detect and
type multiple HPV types infecting patients in an easy and
potentially more accurate way than hybridization techniques,
which may have difficulty sorting multiple types due to cross-
hybridization of signals. Finally, this method has the potential
to quantify HPV according to individual HPV peak areas if
proper internal standards are used. These combined advan-
tages make GP-dHPLC a valuable methodology for HPV
genotyping.
Sequencing has detected many HPV variants with variations
in the E6 (4, 6, 7, 18, 19, 21, 36), E7 (5, 6, 21), LCR (13), and
E2 (10) regions. Previous studies have documented a close
association between these HPV variants and progression to
invasive cervical cancer (11). At present, such variants are
identified by PCR with direct sequencing of the PCR products,
but this may be difficult without a subcloning step if samples
are infected with multiple HPV types. GP-dHPLC is a power-
ful tool for identifying HPV variants, especially those found in
samples with multiple HPV types. In the present study, a num-
ber of HPV variants with sequence variations within the L1
gene were identified. We are unaware of any relationship be-
tween these variants and the recognized variants with varia-
tions in the E6, E7, LCR, and E2 regions. PCR with consensus
or HPV-specific primers with dHPLC has the ability to detect
any sequence variations within any HPV region. We have de-
signed several primer sets that can reliably distinguish a se-
quence divergence of only 1 bp within the E6 and E7 genes of
HPV type 16 (data not shown).
There are some limitations in the detection and genotyping
of genital HPV by GP-dHPLC. First, as is common with all
GP-PCRs, the L1C1-L1C2M primers cannot consistently am-
plify all genital HPV types, especially those with more than five
mismatches, such as HPV type 35. For samples that test neg-
ative for HPV with the L1C1-L1C2M primer set, use of a
second general primer set, such as pU-1M–pU-2R, would im-
prove the sensitivity. Second, we have developed conditions for
detecting only about 20 of the more than 40 genital HPV types
reported (although these 20 types account for over 95% of the
most frequently occurring types), although the specific reten-
tion times of additional HPV-positive controls could be deter-
mined. Third, the retention times of the eluted peaks change
slightly with each new batch of buffer as well as during long
sample runs; they also vary according to which model of the
Wave system is used. Therefore, in addition to optimizing
gradient conditions, it is critical to run HPV-positive controls
periodically between runs with unknown samples.
We have demonstrated that HPV detection and typing by
GP-PCR in combination with analysis by dHPLC are both
reliable and accurate, validating the results obtained by direct
sequencing of the GP-PCR products. As clinical indications for
the detection and typing of HPV expand, GP-dHPLC offers a
new and accurate methodology for HPV analysis.
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16 variant 1 1 5696 AAG-AAA Lys(46)-Lys(46) U37217 8
16 variant 2 2 5637 AGT-AGC Ser(33)-Ser(33) None 2
5696 AAG-AAA Lys(46)-Lys(46)
18 variant 1 1 5701 CCC-CGC Pro(91)-Arg(91) None 4
18 variant 2 2 5619 TTG-ATG Leu(64)-Met(64) None 3
5701 CCC-CGC Pro(91)-Arg(91)





59 variant 1 5683 GAG-GAT Glu(26)-Asp(26) None 2
39 variant 1 5778 GTA-GTG Val(45)-Val(45) None 1
45 variant 1 5675 AGC-AAC Ser(49)-Asn(49) None 1
52 variant 1 5828 AAA-AAG Lys(88)-Lys(88) None 1
a The number indicates the location of the mutation in the complete HPV viral genome given in GenBank. The GenBank accession numbers are as follows: HPV
type 16, K02718; HPV type 18, X05015; HPV type 59, X77858; HPV type 39, M62849; HPV type 45, X74479; HPV type 52, X74481.
b The numbers in parentheses represent the locations of the amino acid in the HPV L1 gene.
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